UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 24, 2003
SCICLONE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-19825 94-3116852
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer)
incorporation) Identification No.)
901 Mariner's Island Blvd., Suite 205
San Mateo, California 94404
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 358-3456
Item 5. Other Events
On September 24, 2003, SciClone Pharmaceuticals, Inc. issued a press
release regarding enrollment in its two phase 3 hepatitis C clinical trials. A
copy of this press release is attached as Exhibit 99.1.
Item 7. Financial Statements and Exhibits.
(c) Exhibits.
Exhibit Description
----- -----------
99.1 Press Release issued by SciClone Pharmaceuticals, Inc., dated
September 24, 2003, regarding enrollment in its two phase 3
hepatitis C clinical trials.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
SCICLONE PHARMACEUTICALS, INC.
Dated: September 24, 2003
/s/Richard A. Waldron
---------------------------------
Richard A. Waldron
Chief Financial Officer